Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ondas-Aktie steigt nach Gründung von KI-Unternehmen mit Palantir-Unterstützung (Investing.com DE) +++ ONDAS Aktie +6,35%

BAUSCH HEALTH Aktie

 >BAUSCH HEALTH Aktienkurs 
5.545 EUR    +2.7%    (TradegateBSX)
Ask: 5.58 EUR / 1001 Stück
Bid: 5.425 EUR / 1030 Stück
Tagesumsatz: 1000 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
BAUSCHHEALTH Aktie über LYNX handeln
>BAUSCH HEALTH Performance
1 Woche: +6,3%
1 Monat: +1,8%
3 Monate: +25,8%
6 Monate: +16,1%
1 Jahr: -2,1%
laufendes Jahr: -11,4%
>BAUSCH HEALTH Aktie
Name:  BAUSCH HEALTH COS.
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA0717341071 / A2JQ1X
Symbol/ Ticker:  BVF (Frankfurt) / BHC (NYSE)
Kürzel:  FRA:BVF, ETR:BVF, BVF:GR, NYSE:BHC
Index:  TSXComp
Profil:  Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company focused on developing, manufacturing, and marketing healthcare products across multiple therapeutic areas. Bausch Health serves the gastroenterology, he..
>Volltext..
Marktkapitalisierung:  2026.57 Mio. EUR
Unternehmenswert:  19455.62 Mio. EUR
Umsatz:  9428.41 Mio. EUR
EBITDA:  3392.04 Mio. EUR
Nettogewinn:  -945.55 Mio. EUR
Gewinn je Aktie:  -2.54 EUR
Schulden:  18528.68 Mio. EUR
Liquide Mittel:  1638.95 Mio. EUR
Operativer Cashflow:  1557.61 Mio. EUR
Bargeldquote:  0.4
Umsatzwachstum:  7.88%
Gewinnwachstum:  -1194.9%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Div. Historie:  10.11.10 - 0.8578€
Insiderhandel:  -
Suchwörter:  BAUSCH HEALTH, BAUSCHHEALTH
Letzte Datenerhebung:  12.10.26
>BAUSCHHEALTH Kennzahlen
Aktien/ Unternehmen:
Aktien: 373.99 Mio. St.
Frei handelbar: 88.6%
Rückkaufquote: -
Mitarbeiter: 20300
Umsatz/Mitarb.: 0.46 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 19.65%
Bewertung:
KGV: -
KGV lG: 1.37
KUV: 0.21
KBV: -
PEG-Ratio: -
EV/EBITDA: 5.74
Rentabilität:
Bruttomarge: 63.03%
Gewinnmarge: -10.03%
Operative Marge: 25.18%
Managementeffizenz:
Gesamtkaprendite: -4.16%
Eigenkaprendite: -
>BAUSCHHEALTH Peer Group
 
12.10.26 - 14:03
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway (PR Newswire)
 
LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management......
12.10.26 - 12:48
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance (Business Wire)
 
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. The Board believes Appio's deep knowledge of the business, global leadership experience and longstanding connection to Bausch + Lomb position him well to build on the company's momentum and lead its next phase of growth. “The opportunity to lead Bausch + Lomb is both a privilege and a responsibility that I embrace with great enthusiasm,” said Appio. “Our company is built on the strength of our people, the quality of our portfolio and a relentless commitment to serving customers and pat...
06.10.26 - 13:03
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 (PR Newswire)
 
LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results......
05.10.26 - 16:45
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies (Zacks)
 
Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile....
01.09.26 - 14:03
Bausch Health Announces Availability of Solta Medical′s Fraxel FTX® in Australia (PR Newswire)
 
The next generation in skin resurfacing technology is available to Australian health care practitioners beginning September 1, 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics......
27.08.26 - 14:06
Bausch Health′s Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners (PR Newswire)
 
This year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. LAVAL, QC, Aug. 27, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business,......
21.08.26 - 19:45
Can Bausch (BHC) Run Higher on Rising Earnings Estimates? (Zacks)
 
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....
21.08.26 - 01:01
Insiderhandel: President, US Pharma verkauft Aktien von Bausch Health Companies im Wert von 258894 USD (Insiderkauf)
 
Lenar, Aimee J. - Vorstand - Tag der Transaktion: 2026-08-19...
10.08.26 - 22:48
Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month (Fool)
 
Much of this was due to a very well-received quarterly earnings report....
08.08.26 - 03:12
Bausch Health (BHC) Q2 2026 Earnings Call Transcript (Fool)
 
Xifaxan surged 26% and Solta margins expanded sharply on strong growth....
06.08.26 - 13:06
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board (PR Newswire)
 
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE: BLCO)(TSX: BLCO), a subsidiary of......
06.08.26 - 13:06
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance (Business Wire)
 
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. (“Bausch Health”), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the company's outstanding common shares, the Bausch + Lomb Board has appointed four new directors, effective Aug. 5, 2026: Thomas J. Appio, CEO, Bausch Health Robert Chersi, founder of Chersi Services LLC, executive director and a professor at Pace University's Center for Governance, Reporting & Regulation and a seasoned director Laurence Paul, MD, co-founder and managing principal of Laurel Crown Partners, LLC, president of The Louis Berkman Company, minority owner of the Pittsburgh Steelers and a director of Crew...
31.07.26 - 05:30
Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY′26 Outlook, NEOG On Watch (RTTNews)
 
Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept after posting robust second-quarter 2026 results, among others....
30.07.26 - 04:00
Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates (Zacks)
 
Bausch (BHC) delivered earnings and revenue surprises of +31.25% and +7.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
29.07.26 - 22:15
Bausch Health Companies Non-GAAP EPS of $1.26 beats by $0.25, revenue of $2.85B beats by $190M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.07.26 - 22:06
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE (PR Newswire)
 
Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $258 million and GAAP Net Income of $260 million GAAP Earnings per Diluted Share......
07.07.26 - 13:03
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026 (PR Newswire)
 
LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results......
01.07.26 - 22:18
Michael Goettler Resigns from Bausch Health′s Board of Directors (PR Newswire)
 
LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.......
28.05.26 - 22:18
Bausch Health′s Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China (PR Newswire)
 
Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system. LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global,......
21.05.26 - 01:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Bausch Health Companies im Wert von 132796 USD (Insiderkauf)
 
Lee, Frank D. - Aufsichtsrat - Tag der Transaktion: 2026-05-19...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wenn zwei beieinander stehen, pflegt′s über den Dritten herzugehen. - Sprichwort Deutschland
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!